Document is current
Any future updates will be listed below
-
Authors
Kweyamba, Prisca A.
Hofer, Lorenz M.
Kibondo, Ummi A.
Mwanga, Rehema Y.
Sayi, Rajabu M.
Matwewe, Fatuma
Lwetoijera, Dickson W.
Tambwe, Mgeni M.
Moore, Sarah J.
- License Information
-
More Information
Article History
Received: 5 September 2024
Accepted: 10 January 2025
First Online: 17 January 2025
Declarations
:
: All adult participants provided written informed consent, while for children under 18 years old, consent was obtained from their parent or guardian, with the children’s assent also sought for their participation. All study volunteers received artemisinin-lumefantrine treatment within 24 h of diagnosis, following the Tanzania Guidelines for Diagnosis and Treatment of Malaria81, administered by a qualified nurse. No adverse effects were reported among the participants during the study period. The study activities were reviewed and approved by the Institutional Review Board of IHI (IHI/IRB/No: 44–2020) and the National Institute for Medical Research Tanzania (NIMR/HQ/R.8a/Vol.IX/3595). All research was performed in accordance to relevant guidelines and regulations.
: The authors declare no competing interests.
